Cancer screening guidelines for older adults are increasingly recommending individualized decision-making rather than relying on age cutoffs. This is in large part due to the individual complexity of aging, such as functional differences, risks of diagnostic procedures, remaining life expectancy, perceived quality of life, and goals of care. The US Preventive Services Task Force (USPSTF) recommends screening for breast cancer until 74 years of age, whereas the American Cancer Society suggests screening as long as the patient is in good health or has a life expectancy of at least 10 years. The USPSTF recommends that men 55 to 69 years of age discuss the potential benefits and harms of prostate-specific antigen screening with their doctor before making an individual decision; for men 70 years and older, the USPSTF and the American Urological Association do not recommend routine screening. Most guidelines recommend that cervical cancer screening should stop at 65 years of age in patients who have adequate prior screening results and do not have high risk. The USPSTF and the American Cancer Society recommend routine colorectal cancer screening until 75 years of age, after which individualized screening can occur based on shared decision-making until 85 years of age. Guidelines recommend lung cancer screening for patients who are 50 to 80 years of age, have at least a 20-pack-year smoking history, and are able and willing to have curative surgery.
For many patients, cancer screening can prevent or improve illness, but it may also cause harms.1 However, most randomized controlled trials of cancer screening tests have not included adults older than 75 years.2,3 It is not always clear whether screening for cancer in older adults leads to net benefit (improved quantity or quality of life), and it may cause more harm in some patients.1 As a result, the screening guidelines of many leading medical societies incorporate individualized decision-making rather than relying on age cutoffs. When discussing cancer screening with older adults, clinicians should consider medical comorbidities, functional status, values and preferences, remaining life expectancy, and goals of care.4
SORT: KEY RECOMMENDATIONS FOR PRACTICE

| Clinical recommendation | Evidence rating | Comments |
|---|---|---|
| The decision to screen for breast cancer in women 75 and older should be individualized based on a shared decision-making process between the patient and physician, considering overall health, life expectancy, and individual preferences.23,25 | B | Meta-analysis of long-term RCTs |
| Prostate-specific antigen–based screening for prostate cancer in men 55 to 69 years of age should be a shared decision, and screening is not recommended in men 70 and older.27,45 | C | Expert opinion and disease-oriented evidence |
| Screening for cervical cancer should stop after 65 years of age in women who have adequate prior screening results and do not have high risk.19 | A | RCTs and meta-analysis of RCTs |
| For patients 76 to 85 years of age, individualized colorectal cancer screening can be offered for a small net benefit.21,49 | B | Meta-analysis of long-term RCTs; cohort studies showing that 1,000 individuals would need to be screened to prevent one death in 10 years |
| Smoking cessation counseling should be offered to older individuals who continue to smoke and are undergoing lung cancer screening.36,38 | B | RCTs and systematic reviews to update the guidelines; the balance of benefits and harms based on consistent results from cohort studies showing a moderate net benefit for individuals at high risk |
RCT = randomized controlled trial.
A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to https://www.aafp.org/afpsort.
DECISION-MAKING FRAMEWORK
Overscreening occurs when clinicians use screening tests at ages outside the recommended range, with a greater frequency than recommended, or when it is unlikely that screening will improve patient outcomes.5 Overscreening for cancer is common in patients with limited life expectancy. For example, mammography has potential harms and is unlikely to improve the outcome for a patient who is 75 years of age with moderate dementia. Failure to consider prognosis in the context of clinical decision-making can lead to poor care.6
Many patients do not receive adequate education on the risks of screening.7 Potential harms include anxiety and discomfort, procedural complications, and further invasive testing. Cancer treatments can cause adverse effects, functional decline, and decreased quality of life. Furthermore, patients with limited life expectancy may be unlikely to live long enough to benefit from screening. Older adults are more prone to overdiagnosis of screening-detected cancers that would not have caused symptoms during their lifetime. Additionally, using time for unnecessary screening can preclude interventions that have clear evidence of benefit, such as reduction of polypharmacy and fall prevention.8,9
A decision-making framework with an individualized approach involves estimating remaining life expectancy and weighing potential benefits and harms in relation to the patient's values and preferences.10 Studies suggest that a life expectancy of at least 10 years is necessary to derive a survival benefit from screening for breast or colorectal cancers.11 One meta-analysis of randomized controlled trials with more than 9 years of follow-up showed that colorectal cancer screening extends life by about 3 months, but no other cancer screening tests reduce all-cause mortality.12 Clinicians should clearly inform patients about the next steps that would follow a positive test result and whether they would be good candidates for further testing and treatment.
Figure 1 presents average life expectancy based on age and sex.13,14 Strong predictors of life expectancy beyond age include the number and severity of comorbid conditions and the presence of functional impairments.6 Table 1 provides prognostic tools to guide clinical judgment in estimating life expectancy, which can then help the clinician determine whether a screening test could be helpful. Table 2 includes decision aids for patients by age and cancer type.14 Table 3 describes benefits, risks, and time to benefit for each screening modality.15–22 Table 4 summarizes cancer screening guidelines for older adults.19,21–38 [corrected]
FIGURE 1.

Upper, middle, and lower quartiles of life expectancy for older women and men. Bars indicate the number of years in which a percentage of the corresponding age and sex cohort will die. For example, in a cohort of men 70 years of age, 25% will die within 8 years (by 78 years of age), 50% will die within 14 years, and 75% will die within 19 years. Presence of conditions such as congestive heart failure, end-stage kidney disease, oxygen-dependent chronic obstructive lung disease, severe dementia, or dependency in activities of daily living reduces life expectancy to less than average for a given age. High functional status and absence of chronic conditions can identify older adults with greater-than-average life expectancy.
Adapted with permission from Salzman B, Beldowski K, De La Paz A. Cancer screening in older patients. Am Fam Physician. 2016;93(8):660, with additional information from reference 13.
TABLE 1. Physician Tools for Cancer Screening Decisions in Older Adults
| Prognostic tools |
| Lee Schonberg Index (community-dwelling adults 50 years and older) |
| Schonberg Index (community-dwelling adults 65 years and older) |
| Palliative Performance Scale |
Decision aids |
| Clinical Frailty Scale |
| Cancer prognosis tool for breast or colorectal cancer |
TABLE 2. Cancer Screening Decision Aids for Older Adults
| Cancer type | Age (years) | Gender | Website |
|---|---|---|---|
| Breast | 75–84 | Female | https://eprognosis.ucsf.edu/decision_aids/Mammography_75-84.pdf |
| 85 and older | Female | https://eprognosis.ucsf.edu/decision_aids/Mammography_85.pdf | |
| Prostate | 50–69 | Male | https://riskcalc.org/PCPTRC/ |
| Colorectal | 70–74 | Female | https://eprognosis.ucsf.edu/decision_aids/Colon_Female_70-74.pdf |
| 75–79 | Female | https://eprognosis.ucsf.edu/decision_aids/Colon_Female_75-79.pdf | |
| 80–84 | Female | https://eprognosis.ucsf.edu/decision_aids/Colon_Female_80-84.pdf | |
| 70–74 | Male | https://eprognosis.ucsf.edu/decision_aids/Colon_Male_70-74.pdf | |
| 75–79 | Male | https://eprognosis.ucsf.edu/decision_aids/Colon_Male_75-79.pdf | |
| 80–84 | Male | https://eprognosis.ucsf.edu/decision_aids/Colon_Male_80-84.pdf | |
| Lung | 65 and older | Male or female | https://cancer.dartmouth.edu/lung-thoracic/lung-cancer-screening |
| https://shouldiscreen.com/English/home |
Information from reference 14.
TABLE 3. Potential Benefits and Harms of Cancer Screening

| Potential benefits | Potential harms |
|---|---|
| Breast cancer | |
| Screening after 69 years of age would prevent 2 deaths per 1,000 patients over 10 years | False-positive results leading to pain, anxiety, and distress Overdiagnosis, which is more likely in older adults Need for follow-up procedures, such as additional mammography, ultrasonography, and breast biopsies |
| Prostate cancer | |
| Per 1,000 patients, screening would prevent 1 death from prostate cancer and result in 3 diagnoses of metastatic prostate cancer over 13 years, with no reduction in all-cause mortality | Overdiagnosis resulting in unnecessary anxiety, biopsies, and overtreatment (eg, excess radiation, overuse of androgen deprivation therapy) Hematuria, hematospermia, urinary tract infection, and sepsis caused by biopsies |
| Cervical cancer | |
| High-risk human papillomavirus testing alone or cotesting with cervical cytology would prevent 1 cancer diagnosis per 1,000 women vs cytology alone | False-positive results Additional procedures such as colposcopy can lead to scarring and fertility problems Overtreatment of low-grade squamous intraepithelial lesion |
| Colorectal cancer | |
| An estimated 26 colorectal cancer deaths would be prevented per 1,000 patients 45–75 to years of age | Bleeding and perforation Cardiovascular and pulmonary complications Death |
| Lung cancer | |
| To avoid 1 lung cancer death, 194 women and 603 men need to be screened; therefore, 5 women and 2 men per 1,000 patients screened are likely to benefit | False-positive results Additional imaging Invasive procedures, such as biopsies and surgery |
TABLE 4. Cancer Screening Guidelines for Older Adults
| Organization | Recommendations |
|---|---|
| Breast cancer | |
| USPSTF and AAFP | Screen biennially until 74 years of age, after which there is insufficient evidence to support screening If screening is offered, physicians should explain the uncertainty about the balance of benefits and harms |
| ACS | Continue screening every 1–2 years as long as the patient has good overall health and a life expectancy ≥ 10 years |
| American College of Obstetricians and Gynecologists | For patients older than 75, base the decision to stop screening on a shared decision-making process that includes a discussion of the patient's health status and longevity |
| Prostate cancer | |
| USPSTF, AAFP, and AUA | For men 55–69 years of age who are considering periodic prostate cancer screening, discuss the risks and benefits and engage in shared decision-making that enables an informed choice Do not screen after 70 years [corrected] AUA recommends a screening interval of 2–4 years |
| ACS | Men who choose to be tested and have a prostate-specific antigen level < 2.5 ng/mL (2.5 mcg/L) may need to be retested only every 2 years Annually screen men whose prostate-specific antigen level is ≥ 2.5 ng/mL Stop screening when a patient has a life expectancy < 10 years |
| Cervical cancer | |
| USPSTF and AAFP | Do not screen women older than 65 who have adequate prior screening results and are not otherwise at high risk for cervical cancer |
| ACS | Screening can be stopped in patients older than 65 who have not had cervical intraepithelial neoplasia grade 2 or more severe disease in the past 25 years and have adequate negative screening results in the past 10 years |
| American College of Obstetricians and Gynecologists | Do not screen patients older than 65 when there is no history of cervical changes, in addition to three consecutive negative cytology results, two consecutive negative human papillomavirus tests, or two consecutive negative cotesting results within the past 10 years; the most recent test should have been performed within the past 3 or 5 years, depending on the type of test |
| Colorectal cancer | |
| USPSTF and AAFP | Screen all patients 50–75 years of age Selectively offer screening to patients 76–85 years of age; evidence indicates that the net benefit of screening all people in this age group is small |
| National Cancer Institute | Regularly screen patients who are in good health with life expectancy > 10 years through 75 years of age For patients 76–85 years of age, the decision to be screened should be based on a person's preferences, life expectancy, overall health, and prior screening results Do not screen patients older than 85 |
| Lung cancer | |
| USPSTF and AAFP | Annually screen for lung cancer with low-dose computed tomography in patients 50–80 years of age who have a 20-pack-year smoking history and currently smoke or have quit within the past 15 years |
| ACS | Annually screen for lung cancer with low-dose computed tomography in all patients 50–80 years of age who have a 20-pack-year smoking history |
AAFP = American Academy of Family Physicians; ACS = American Cancer Society; AUA = American Urological Association; USPSTF = US Preventive Services Task Force.
BREAST CANCER
More than 40% of all breast cancers and 57% of all breast cancer deaths occur in women 65 and older, and higher death rates and poorer outcomes are associated with increased age beyond 65 years.24,39 Randomized controlled trials of screening mammography have not typically included women older than 74, so it is unclear whether screening mammography reduces breast cancer mortality in this group.40 Observational studies have shown an association between mammography in women 75 and older and lower breast cancer mortality.41
However, the harms may outweigh the benefits for many women in their late lives. Treatment of breast cancer in older adults is associated with greater morbidity, including an increased risk of postoperative complications and toxicity from chemotherapy.42
The American Cancer Society advises physicians to continue screening patients with mammography as long as they are in good overall health and have a life expectancy of at least 10 years.25 The United States Preventive Services Task Force (USPSTF) finds that the evidence is insufficient to assess the balance of benefits and harms of screening women 75 years and older.23 Therefore, the decision to continue mammography screening in patients 75 and older should be individualized and consider potential benefits and harms in the context of a woman's overall health, perceived quality of life, life expectancy, values, and preferences.
Regular physical breast examinations in this age range, including those performed by health professionals (clinical breast examinations) or patients (self-examinations), are no longer recommended due to a lack of clear benefit.25 The American Cancer Society suggests consideration of magnetic resonance imaging of the breast in addition to mammography for women in good health who have a high risk of breast cancer due to BRCA-1 or BRCA-2 mutations or a high-risk genetic syndrome, lifetime breast cancer risk of 20% or more, or prior radiation to the chest.25
PROSTATE CANCER
Prostate cancer is the third most common cancer in the United States, accounting for 9.5% of new cancer cases, 5% of cancer deaths, and 2.3% of all deaths.43 Approximately 11% of men will receive a prostate cancer diagnosis during their lifetime, with 98% surviving 5 years or more.44 Prostate cancer has a higher prevalence and mortality rate in men who are older adults or who are Black and in those with a family history of prostate cancer.18
An evidence review commissioned by the USPSTF concluded that prostate-specific antigen (PSA)–based screening programs in 1,000 men 55 to 69 years of age led to 100 diagnoses over 13 years and prevented 1.3 deaths from prostate cancer. However, no reduction in all-cause mortality was found, and screening led to substantial harms due to treatment complications, such as erectile dysfunction and incontinence. Due to the balance of benefits and harms in the age range of the study, the review concluded that men 70 and older receive no benefit from PSA-based screening.27,45
The USPSTF recommends that PSA-based screening in men 55 to 69 years of age be an individual decision after discussion of potential benefits and harms. Potential harms include false-positive results that require additional testing and possible prostate biopsy; complications of biopsy, including infection; overdiagnosis and overtreatment; and treatment complications.27 Guidelines from the American Urological Association recommend prostate cancer screening every 2 to 4 years in men 50 to 69 years of age as long as the patient and clinician agree during the shared decision-making process. The guidelines also clarify that clinicians may use digital rectal examination alongside PSA testing to determine the risk of clinically significant prostate cancer.29,30
Routine screening is not recommended in men 70 and older. Many men overestimate the benefits of screening for prostate cancer. However, after engaging in shared decision-making discussions, patients are less likely to request screening.46,47
CERVICAL CANCER
In the United States, 21% of new cervical cancer cases and 38% of deaths occur in patients 65 and older.35 The USPSTF recommends screening patients 30 to 65 years of age every 3 years with cervical cytology; every 5 years with high-risk human papillomavirus (HPV) testing; or every 5 years with high-risk HPV testing and cervical cytology (cotesting).19 The updated draft recommendations prioritize high-risk HPV testing alone over cotesting or cytology and includes the option of using patient-collected specimens. The American Cancer Society also recommends high-risk HPV testing every 5 years as the preferred screening method.32 The USPSTF recommends against screening patients older than 65 as long as they have adequate prior screening results and do not have high risk.19 The recommendations of the American Academy of Family Physicians align with those of the USPSTF.32
Joint guidelines from the American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society of Clinical Pathology define adequate screening as three consecutive negative cytology results or two consecutive negative cotesting results within 10 years; the most recent result must be within the past 5 years.35 One study of cervical cancer survivors found that 50% reported that they had not been screened in the 5 years preceding the diagnosis.48
COLORECTAL CANCER
Approximately 55% of new diagnoses of colorectal cancer occur in patients 65 and older.49 The USPSTF recommends screening for colorectal cancer in all patients 45 to 75 years of age.20 Recommended screening modalities include stool-based tests (ie, high-sensitivity guaiac-based fecal occult blood testing, fecal immunochemical testing [FIT], or multitarget stool DNA or FIT-DNA testing) and direct visualization (ie, colonoscopy, flexible sigmoidoscopy, or computed tomography colonoscopy).21 The most commonly used screening tests are FIT and colonoscopy.
Due to a variable net benefit based on each patient's health and life expectancy, the USPSTF recommends individualized screening after shared decision-making in patients 76 to 85 years of age.20,21 Screening in adults older than 85 is not recommended.34 The American Geriatrics Society recommends that colorectal cancer screening continue as long as the patient has at least 10 years of life expectancy.31 A population-based survey found that 56% of older adults received screening despite having life expectancy of less than 10 years, whereas some with a life expectancy of more than 10 years were not screened.50 Risk of harms or adverse events (eg, perforation of the colon, bleeding, cardiovascular and pulmonary complications, death) with screening increases with age. For example, adverse events with colonoscopy were 26 per 1,000 in patients 65 and older and 35 per 1,000 in patients 80 and older.51 Transitioning to primary FIT screening in older patients is an option to reduce potential harm.
LUNG CANCER
The USPSTF recommends annual lung cancer screening with low-dose computed tomography in patients 50 to 80 years of age who have at least a 20-pack-year smoking history and have smoked in the past 15 years. Screening should be discontinued after the patient has not smoked for 15 years or if they develop a health problem that substantially limits life expectancy or become unable to have curative lung surgery.52 Guidelines were initially based on the National Lung Screening Trial and have been further supported by the NELSON (Nederlands-Leuvens Longkanker Screenings Onderzoek) trial and additional meta-analyses.22,53
The number needed to screen over 65 years was 320 to prevent one lung cancer death and 210 to prevent one death from any cause. Of patients undergoing screening with low-dose computed tomography, 98.5% were found to be cancer-free over the next 12 months. Abnormalities were found in 1 out of 7 patients, but 90% of these findings were not cancer.53 Screening prompts additional imaging in almost one-third of patients, and 2.8% of all screened patients will undergo an invasive procedure.54 The NELSON trial rescreened after 1, 3, and 5.5 years and achieved lower biopsy rates and a greater reduction in mortality than the National Lung Screening Trial, which screened annually.55
Smoking cessation counseling should be offered to older individuals who continue to smoke and are undergoing lung cancer screening.36,38
CONSIDERATIONS FOR PRACTICE
Many physicians inappropriately recommend cancer screening for older patients with advanced illness who would not benefit, perhaps because they feel unprepared to talk about stopping screening. Furthermore, many older patients perceive cancer screening as a routine part of their health care and may not understand its limitations.56
Studies show that most older adults with advanced illness want to discuss the possibility of stopping cancer screening and be informed of their prognosis so that they can make medical decisions. Surrogate decision-makers for those affected by dementia may be open to discussions about screening cessation and shared decision-making regarding treatments that focus on quality of life, burdens, and benefits.3 Given the uncertainty of the relative benefits and harms of cancer screening in older adults, the patient's preferences should be a key consideration.56 Decision aids can improve patient involvement, knowledge, and realistic perceptions of outcomes.
Experts recommend that physicians introduce the idea of stopping cancer screening in advance to establish the expectation that a time will come when the burdens of screening will outweigh the potential benefits.57 Discussions should be revisited periodically, or in the context of the patient's health status, to help them weigh the benefits and harms of screening and to clarify patient preferences. It is especially valuable to convey that a decision to stop cancer screening does not translate to decreased health care or worse outcomes. Rather, discussions can focus on health promotion strategies with shorter time to benefit, such as exercise, nutrition, immunizations, and support with basic or instrumental activities of daily living.
Discussion around multicancer blood-based tests has increased. However, studies that demonstrate more benefit than harm compared with standard cancer screening modalities are lacking. Primary care physicians should not order them for adults of any age.
This article updates previous articles on this topic by Salzman et al.14 and Albert and Clark.58
Data Sources: A PubMed search was completed in Clinical Queries using the key terms cancer screening and older adult. The search included meta-analyses, randomized controlled trials, clinical trials, and reviews. The USPSTF, Cochrane Database of Systematic Reviews, and Essential Evidence Plus were also searched. We critically reviewed studies that used patient category of age primarily, and in some cases race and gender were also included. Search dates: October 23, 2024, and September 22, 2025.
